Insider transaction details
Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics (NASDAQ: UTHR), sold a total of 9,440 shares of the company's common stock on March 13, 2026. The proceeds from those sales were approximately $5.1 million, with execution prices ranging from $535.4265 to $542.035 per share.
Also on March 13, 2026, Rothblatt exercised stock options to acquire 9,500 shares of United Therapeutics common stock at an exercise price of $146.03 per share. The total value associated with that option exercise was $1,387,285.
Trading plan and option details
Both the stock sales and the option exercise were carried out pursuant to a pre-established 10b5-1 trading plan that Rothblatt adopted on November 7, 2025. The plan is scheduled to remain in effect until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options that expire on March 17, 2027.
Post-transaction ownership
Following these transactions, Rothblatt directly holds 130 shares of United Therapeutics common stock. In addition to direct ownership, Rothblatt retains indirect interests in company shares through family trusts.
Clinical and corporate developments at United Therapeutics
In separate corporate news, United Therapeutics reported that its phase 3 TETON-2 study results were published in the New England Journal of Medicine. The study showed that nebulized Tyvaso produced a significant improvement in lung function for patients with idiopathic pulmonary fibrosis, according to the company's announcement.
The company also disclosed a new $2 billion stock repurchase program. That program includes an initial $1.5 billion accelerated share repurchase agreement with Citibank, while the remaining $500 million is designated for additional buybacks at the company's discretion over the following year.
Analyst reactions
Following these developments, Cantor Fitzgerald raised its price target for United Therapeutics shares to $625 and maintained an Overweight rating, citing favorable expectations tied to trial progress. TD Cowen reiterated a Buy rating with a $575 price target, expressing continued confidence in the company's franchise.
Context and closing
The combination of Rothblatt's cash sales and option exercise under a 10b5-1 framework, the publication of positive phase 3 data, and the launch of a sizable repurchase program represents a cluster of insider activity and corporate actions occurring on and around March 13, 2026. These elements were confirmed in company disclosures and analyst commentary as described above.